🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
This phase Ib trial studies the side effects of pembrolizumab and trametini...
Status
Completed
Location
University of California Davis Comprehensive Cancer Center
Start Date
2018-06-26
Trial ID
NCT03299088
Treatments Being Tested
This phase II trial studies how well dabrafenib, trametinib, and spartalizu...
Status
Terminated
Location
M D Anderson Cancer Center
Start Date
2020-01-29
Trial ID
NCT04310397
Treatments Being Tested
This research study is studying a combination of drugs as a possible treatm...
Status
Unknown
Location
Massachusetts General Hosital Cancer Center
Start Date
2018-10-15
Trial ID
NCT03668431
Treatments Being Tested
This is a single arm phase II trial focused on how dabrafenib and trametini...
Status
Active Not Recruiting
Location
M D Anderson Cancer Center
Start Date
2014-10-22
Trial ID
NCT02231775
Treatments Being Tested
This phase 2 trial will investigate the efficacy and safety of trametinib a...
Status
Completed
Location
Universitair Ziekenhuis Brussel
Start Date
2019-01-28
Trial ID
NCT04059224
Treatments Being Tested
This study is a Phase 1 dose-escalation open-label study to determine the r...
Status
Completed
Location
GSK Investigational Site
Start Date
2010-05-04
Trial ID
NCT01138085
Treatments Being Tested
This study is being done to find out if the combination of dabrafenib, tram...
Status
Withdrawn
Location
University of Texas Southwestern Medical Center
Start Date
2016-10
Trial ID
NCT02915666
Treatments Being Tested
GSK1120212 is a potent and highly selective inhibitor of MEK phosphorylatio...
Status
Completed
Location
GSK Investigational Site
Start Date
2010-08
Trial ID
NCT01231581
Treatments Being Tested
This phase I/II trial tests the safety, side effects, and best dose of PLX2...
Status
Withdrawn
Location
Multiple Locations
Start Date
2023-01-13
Trial ID
NCT05677373
This is a phase 2 study (the second phase in testing a new drug or combinat...
Status
Completed
Location
Juravinski Cancer Center
Start Date
2016-04
Trial ID
NCT02428270
Treatments Being Tested